ArticleCancer discovery2018
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 240 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
240citing papers in PubMed, 2 pooled it
13.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
240 citing papers in PubMed, 2 syntheses or guidelines pooled it, 374 citations in OpenAlex.
- Application advances of habitat imaging based on CT or PET/CT: a systematic review.La Radiologia medica · 2026Pooled it
- Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis.BMC cancer · 2023Pooled it
- Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer.Cell reports. Medicine · 2025Trial
- Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.Nature medicine · 2024Trial
- Trial
- Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer.Cancer discovery · 2024Trial
- Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer.Nature communications · 2022Trial
- Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.The Lancet. Oncology · 2022Trial
- Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.Journal of hematology & oncology · 2021Trial
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.The Lancet. Oncology · 2020Trial
- Navigating Antibody-Drug Conjugate Sequencing in Gastric Cancer: Cross-Resistance Biology, Target Switching, and Decision-Making Frameworks for the Post-Progression Landscape.Current oncology reports · 2026Review
- Dynamic HER2 reassessment and precision sequencing after trastuzumab in HER2-positive advanced gastric cancer.ESMO gastrointestinal oncology · 2026Review
- Targetable genes associated with hematogenous metastasis in gastric cancer using the TCGA database.Korean journal of clinical oncology · 2026Article
- Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- MET-amplified gastric cancers exhibit co-amplifications of BRAF, CDK6, and EGFR.The journal of pathology. Clinical research · 2026Article
- ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers.ESMO open · 2026Article
- Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Transcriptional Reinforcement of the HER2-RAS Network in HER2-Positive Gastric Cancer: The RUNX-SOS1 Axis in Context.Cancer science · 2026Review
- JAK2 and NOTCH2 in gastric cancer - NOTCH2 is an independent prognosticator of poor patient outcome.Virchows Archiv : an international journal of pathology · 2026Article
180 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
40 authors at 1 institution in 1 country.
Yelena Y JanjigianDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York. janjigiy@mskcc.org.
Francisco Sanchez-VegaMarie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Philip JonssonHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Walid K ChatilaMarie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jaclyn F HechtmanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Geoffrey Y KuDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Jamie C RichesDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Yaelle TuvyDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Ritika KundraMarie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Nancy BouvierMarie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Efsevia VakianiDepartment of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Jianjiong GaoMarie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Zachary J HeinsMarie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Benjamin E GrossMarie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
David P KelsenDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Liying ZhangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Vivian E StrongDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Mark SchattnerDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Hans GerdesDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Daniel G CoitDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Manjit BainsDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Zsofia K StadlerDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Valerie W RuschDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
David R JonesDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Daniela MolenaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Jinru ShiaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Mark E RobsonDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Marinela CapanuDepartment of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Sumit MiddhaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Ahmet ZehirDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
David M HymanDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Maurizio ScaltritiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Marc LadanyiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Neal RosenDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
David H IlsonDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Michael F BergerMarie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Laura TangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Barry S TaylorMarie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
David B SolitDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Nikolaus SchultzMarie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Memorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MDisparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2MStudies on oncoprotein-induced feedback: Basic and therapeutic implicationsR35CA210085 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROSEN, NEAL · 2016 to 2022
$7.3MDevelopment of BRCA1-mimetic drugs for breast cancerR01CA150646 · NCI · GEORGETOWN UNIVERSITY · PI ROSEN, ELIOT M. · 2010 to 2014
$2.8MNCATS NIH HHS UL1 TR002384NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA150646NCI NIH HHS R35 CA210085
Abstract
The incidence of esophagogastric cancer is rapidly rising, but only a minority of patients derive durable benefit from current therapies. Chemotherapy as well as anti-HER2 and PD-1 antibodies are standard treatments. To identify predictive biomarkers of drug sensitivity and mechanisms of resistance, we implemented prospective tumor sequencing of patients with metastatic esophagogastric cancer. There was no association between homologous recombination deficiency defects and response to platinum-based chemotherapy. Patients with microsatellite instability-high tumors were intrinsically resistant to chemotherapy but more likely to achieve durable responses to immunotherapy. The single Epstein-Barr virus-positive patient achieved a durable, complete response to immunotherapy. The level of
Indexed as
Biomarkers, TumorEsophageal NeoplasmsHumansImmunotherapyProspective StudiesStomach NeoplasmsBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.